GlassScriptPhysician profile
Jan M Levesque
NPI 1194027540
$2,929.39
in general payments reported to CMS, 2019-2025
22 companies · $861 in 2025
The $861 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $952 · 2022: $22.67 · 2023: $717 · 2024: $377 · 2025: $861.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,955.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,954.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $764.50 | 2021-2024 | Farxiga |
| Novo Nordisk INC | $354.83 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $321.26 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Lilly USA, LLC | $300.38 | 2021-2025 | Mounjaro, Zepbound |
| Tandem Diabetes Care, INC. | $193.08 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Glaxosmithkline, LLC. | $137.41 | 2023-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Amgen INC. | $120.43 | 2025 | Tepezza |
| Bayer Healthcare Pharmaceuticals INC. | $118.89 | 2023 | |
| Sanofi-Aventis U.S. LLC | $111.52 | 2021-2024 | |
| Abbvie INC. | $68.13 | 2024-2025 | |
| Sequel Med Tech, LLC | $67.19 | 2025 | Twiist |
| Beta Bionics, INC. | $55.07 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Merck Sharp & Dohme LLC | $51.81 | 2023-2025 | Rotateq, Gardasil 9, Vaxelis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.89 | 2024 | Jardiance |
| Collegium Pharmaceutical, INC. | $45.92 | 2024-2025 | Xtampza |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $45.00 | 2025 | Minimed 780g |
| Abiomed | $32.11 | 2024 | Impella |
| Pfizer INC. | $23.84 | 2025 | |
| Insulet Corporation | $21.00 | 2023 | Omnipod |
| Takeda Pharmaceuticals U.S.A., INC. | $18.92 | 2023 | Trintellix |
| Currax Pharmaceuticals LLC | $14.35 | 2025 | Contrave |
| Exact Sciences Corporation | $13.86 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jan Levesque listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.